Phosphodiesterase Inhibitors

04/27/2004 - "We also present the existing evidence for the efficacy of 3 phosphodiesterase inhibitors, the most widely used class of agents for erectile dysfunction."
03/01/2008 - "Despite the proven clinical efficacy of phosphodiesterase inhibitors in the treatment of erectile dysfunction (ED), some patients do not respond to the medication. "
09/22/2007 - "[From the Cochrane Library: Phosphodiesterase inhibitors are effective in treating erectile dysfunction in diabetic men]."
10/01/2003 - "Oral phosphodiesterase inhibitors have become the mainstay of treatment for erectile dysfunction. "
05/01/2005 - "With phosphodiesterase inhibitors, a safe and effective oral therapy has emerged for erectile dysfunction. "

01/01/1989 - "The balance between the energy saving and the energy consuming effects may determine the efficacy of phosphodiesterase inhibitors, especially in the long-term treatment of chronic heart failure."
06/01/2002 - "After several early studies using high doses of phosphodiesterase inhibitors in patients with severe heart failure suggested adverse consequences, they fell out of favor. "
01/01/1991 - "A review of studies concerning the effects of digitalis, adrenoceptor stimulating or blocking agents, as well as phosphodiesterase inhibitors on hemodynamics and the physical state of heart failure patients is presented. "
04/01/2014 - "This conservative approach in INTERMACS profile one patients warrants very early introduction of adequate medical heart failure therapy under the umbrella of a combination of short-term mechanical circulatory and inotropic support by phosphodiesterase inhibitors. "
06/01/2012 - "The logistic stepwise regress analysis showed that AMI (OR, 5.62, 95% CI=2.56-12.33), heart failure (OR, 2.68, 95% CI=1.67-4.29), age≥60 years (OR, 2.01, 95% CI=1.22-3.30), and medication of phosphodiesterase inhibitors (OR, 1.67, 95% CI=1.15-2.42) were independent risk factors for in-hospital mortality and one-year follow-up MACEs, while statins (OR, 0.23, 95% CI=0.06-0.91) and IM therapy (OR, 0.69, 95% CI=0.49-0.97) were protective factors. "

02/01/2013 - "Additive effect of phosphodiesterase inhibitors in control of pulmonary hypertension after congenital cardiac surgery in children."
02/11/2010 - "Phosphodiesterase inhibitors for pulmonary hypertension."
02/11/2010 - "Phosphodiesterase inhibitors for pulmonary hypertension."
07/01/2008 - "Phosphodiesterase inhibitors for the treatment of pulmonary hypertension."
12/01/2003 - "Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review."

02/01/2006 - "Protective effects of phosphodiesterase inhibitors on lung function and remodeling in a murine model of chronic asthma."
02/24/1995 - "It is concluded that phosphodiesterase inhibitors may be very useful in the treatment of bronchial asthma."
01/01/2006 - "The potential role of phosphodiesterase inhibitors in the management of asthma."
01/01/2006 - "Functional antagonists, which modulate intracellular signalling pathways within the smooth muscle (beta-agonists and phosphodiesterase inhibitors), have been used for decades with success, but are not universally effective and patients continue to suffer with exacerbations of asthma using these drugs. "
01/01/2004 - "The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma."

08/01/2013 - "Phosphodiesterase inhibitors (PDE-Is) have been shown to be beneficial in animal models of tuberculosis. "
08/01/2013 - "Adjuvant host-directed therapy with types 3 and 5 but not type 4 phosphodiesterase inhibitors shortens the duration of tuberculosis treatment."
01/01/2012 - "Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model."
12/01/2015 - "With phosphodiesterase inhibitors (PDE-Is) showing significant promise in shortening tuberculosis treatment, we assessed the effect of roflumilast, an FDA-approved type 4 PDE-I, in both acute and chronic murine models of tuberculosis. "